🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing around the world, with figures suggesting more than 82 million infections each year. Notably increased rates are observed in Africa and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the context of rising global incidence, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This approval marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

Based on data detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which combines a dual-drug approach. The research involved over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have voiced hope. Access to a single-dose, oral treatment of this kind is described as a "revolutionary step" for public health efforts. This is deemed vital to alleviate the strain of the disease for people and to prevent the spread of extremely resistant gonorrhoea around the world.